Document type
ArticlePublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/219391
Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal hypertension: A randomized, single-blind clinical trial
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Background and aims
Continuous infusion (CI) of terlipressin may result in a more sustained reduction in portal pressure with fewer adverse effects than administered as a bolus. This study aimed to compare the hepatic and cardiopulmonary hemodynamic effects and safety profiles of bolus vs terlipressin CI.
Methods
This is a single-center, single-blinded, double-dummy, parallel-group, clinical trial in which 38 patients with cirrhosis and portal hypertension were randomized to receive: 1mg bolus of terlipressin + CI of placebo (TERLBOL n=12), bolus of placebo + CI of terlipressin (2mg/day or 4mg/day if <10% reduction in hepatic venous pressures gradient (HVPG) at 30min of infusion) (TERLINF n=14) or a bolus of octreotide (50mcg) + CI of octreotide (50mcg/h) (OCTR n=12) as an additional control group. HVPG, cardiopulmonary pressures and cardiac output were measured at baseline, after 30, 60 and 120 minutes.
Results
Sixty-eight percent of patients were male, with median age 59-years. There were no significant differences in baseline characteristics. TERLBOL group: there was a non-significant reduction in HVPG (at 120min, -4.9%; p:0.14), however, cardiopulmonary and mean arterial pressures significantly increased, while cardiac output and heart rate significantly decreased. TERLINF group: there were non-significant changes in cardiopulmonary hemodynamics or HVPG (NS) despite doubling the infusion dose after 30min in 13/14 patients. OCTR group: there was a non-significant reduction in HVPG (at 120min, -4.9%; p:0.08) and pulmonary capillary pressure significantly decreased. All treatments were well tolerated, and no adverse events were observed.
Conclusion
There were non-significant reductions in HVPG with the three therapeutic strategies. Further investigations are warranted to determine the optimal dosing strategy for CI of Terlipressin in patients with cirrhosis and portal hypertension.
Subject
Subject (English)
Citation
Citation
PEREZ CAMPUZANO, Valeria, et al. Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal hypertension: A randomized, single-blind clinical trial. JHEP Reports. 2025. Vol. vol 7, num. 1-7. ISSN 2589-5559. [consulted: 18 of June of 2026]. Available at: https://hdl.handle.net/2445/219391